Nonpartisan civic infrastructure
AllCiv·Legis1
·

S. 2886

BillFederalSenateIn Committee
To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.
About This Bill
Committee
Latest Action · September 21, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced
September 21, 2023
Cosponsors (3)
3D 0R
View PDF ↗
SummaryFull TextCommentsAnnotations

Full Text

The official full text of this bill isn’t available inside AllCiv yet. Read it on Congress.gov:

A plain-language summary is on the Summary tab — you can highlight and annotate it there.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.